

## StoP-AD Centre at the Douglas Institute

Many studies are underway with participant at risk of developing Alzheimer's disease (e.g. : genetic factors) but with no cognitive decline.

The main objective of the study is:

- To characterize the asymptomatic phase of the disease;
- Invert or slow down disease progression before first symptoms appears;
- Develop a disease progression score in the asymptomatic phase taking into account several variables.

Age criteria: 60 years old and more, with an exception to people aged between 55-59.

People who are eligible can be enrolled into clinical trials evaluating the effect of two drugs:

Naproxen: anti-inflammatory molecule – recruitment finished

and

Probucol: hypolipidemic molecule – First phase recruitment over. A second phase will start in 2018.

If you want to know more about the study or want to participate, please fill in the online questionnaire or call the research center at 1 855 888-4485 (Free toll) or 514 761-6131 #3940.

A nurse will call you back for a phone evaluation.

### *Facts about StoP-Alzheimer Centre*

- Clinical investigation of persons who are at risk of AD but who are presently symptom-free. These people will be the participants in a program called PREVENT-AD that will examine the effects of different prevention strategies designed to slow or reverse the disease.
- To support basic science efforts of two kinds
- Investigation of mechanisms that may explain the results obtained from our clinical research. If our research shows that some interventions can slow or reverse the course of pre-symptomatic Alzheimer's disease, we will want to explore how and why these treatments are effective. This second line of inquiry must await the early results of the PREVENT-AD program.
- Investigation into the biological mechanisms that may cause or accelerate the progress of Alzheimer's disease in its earliest stages.